Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05440942 · ClinicalTrials.gov registry record · Phase 1
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1 study, sponsored by Peter Hosein, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05440942 is a Phase 1 study that has completed, run by Peter Hosein, MD. The registered enrollment target is 28 participants.
The verdict
NCT05440942, a Phase 1 study, has completed, sponsored by Peter Hosein, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR\^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Interventions
- DRUG Retifanlimab
- DRUG Ruxolitinib
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05440942
The ClinicalTrials.gov registry entry for NCT05440942 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter Hosein, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Retifanlimab is the first listed.
NCT05440942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05440942 about?
NCT05440942 is a clinical study titled "Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR\^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT05440942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-01-19. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05440942?
The interventions under investigation include: Retifanlimab (DRUG), Ruxolitinib (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT05440942?
This trial is sponsored by Peter Hosein, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.